Chloroquine and Hydroxychloroquine is an antimalarial, disease-modifying anti-rheumatic drug. In China and France, some studies provided some indications of possible benefits against pneumonia caused by COVID-19 but need confirmation through randomized trials.
There are many trials going on now to test the efficacy of these drugs. Mechanism of action of hydroxychloroquine includes multiple effects including reduced cytokine production, inhibits immune activation and also interferes with lysosomal activity and membrane stability.
Chloroquine was discovered in 1934 by Hans AndersagIt is usually available as a generic medication. Common side effects include muscle problems, loss of appetite, diarrhoea, and skin rash and serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels. It is a member of the drug class 4-aminoquinoline.
During pregnancy, a woman undergoes with multiple interactions with the health care system that increases her chance of getting infected. So therefore, managing pregnant population presents a unique challenge during COVID-19. The physiological changes and partial immune suppression during pregnancy makes pregnant women and new-born babies susceptible to several infections. Post-partum haemorrhage, maternal sepsis, preeclampsia, and premature rupture of membrane are the most common COVID-19-induced adverse events reported among pregnant women.
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan